JP2020506159A - 組み合わせでのＷｎｔ阻害剤および抗ＰＤ−１抗体分子の投与スケジュール - Google Patents

組み合わせでのＷｎｔ阻害剤および抗ＰＤ−１抗体分子の投与スケジュール Download PDF

Info

Publication number
JP2020506159A
JP2020506159A JP2018550764A JP2018550764A JP2020506159A JP 2020506159 A JP2020506159 A JP 2020506159A JP 2018550764 A JP2018550764 A JP 2018550764A JP 2018550764 A JP2018550764 A JP 2018550764A JP 2020506159 A JP2020506159 A JP 2020506159A
Authority
JP
Japan
Prior art keywords
day
administered
treatment
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018550764A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506159A5 (enExample
Inventor
ラッセル ドブソン，ジェイソン
ラッセル ドブソン，ジェイソン
ムーディー，スーザン
エリス マクラフリン，マーガレット
エリス マクラフリン，マーガレット
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2020506159A publication Critical patent/JP2020506159A/ja
Publication of JP2020506159A5 publication Critical patent/JP2020506159A5/ja
Priority to JP2022139650A priority Critical patent/JP2022174157A/ja
Priority to JP2024095809A priority patent/JP2024133495A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2018550764A 2017-02-14 2018-02-12 組み合わせでのＷｎｔ阻害剤および抗ＰＤ−１抗体分子の投与スケジュール Pending JP2020506159A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022139650A JP2022174157A (ja) 2017-02-14 2022-09-02 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
JP2024095809A JP2024133495A (ja) 2017-02-14 2024-06-13 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022139650A Division JP2022174157A (ja) 2017-02-14 2022-09-02 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール

Publications (2)

Publication Number Publication Date
JP2020506159A true JP2020506159A (ja) 2020-02-27
JP2020506159A5 JP2020506159A5 (enExample) 2021-03-25

Family

ID=61526841

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018550764A Pending JP2020506159A (ja) 2017-02-14 2018-02-12 組み合わせでのＷｎｔ阻害剤および抗ＰＤ−１抗体分子の投与スケジュール
JP2022139650A Withdrawn JP2022174157A (ja) 2017-02-14 2022-09-02 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
JP2024095809A Pending JP2024133495A (ja) 2017-02-14 2024-06-13 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022139650A Withdrawn JP2022174157A (ja) 2017-02-14 2022-09-02 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール
JP2024095809A Pending JP2024133495A (ja) 2017-02-14 2024-06-13 組み合わせでのＷｎｔ阻害剤および抗ＰＤ－１抗体分子の投与スケジュール

Country Status (12)

Country Link
US (2) US11406633B2 (enExample)
EP (1) EP3582811B1 (enExample)
JP (3) JP2020506159A (enExample)
KR (2) KR20190112801A (enExample)
CN (2) CN110267682A (enExample)
AU (1) AU2018221557C1 (enExample)
CA (1) CA3051989A1 (enExample)
IL (1) IL268341B2 (enExample)
MX (1) MX2019009630A (enExample)
RU (1) RU2767533C2 (enExample)
TW (1) TWI771372B (enExample)
WO (1) WO2018150312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
KR20170060042A (ko) 2014-09-13 2017-05-31 노파르티스 아게 Alk 억제제의 조합 요법
EP3389712B1 (en) * 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
JP7451506B2 (ja) * 2018-09-27 2024-03-18 ムスク・ファウンデイション・フォー・リサーチ・ディベロップメント がんの治療用の薬学的組合せ
WO2020236078A1 (en) * 2019-05-22 2020-11-26 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169281A1 (zh) * 2015-04-21 2016-10-27 永济新时速电机电器有限责任公司 辅助变流器和车辆

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) * 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CA2985818A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions comprising an antagonist of porcupine and a pd-l/pd-1 axis antagonist for immunotherapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016169281A1 (zh) * 2015-04-21 2016-10-27 永济新时速电机电器有限责任公司 辅助变流器和车辆

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF HISTORY FOR NCT01351103, JPN6022012250, 2016, ISSN: 0005107995 *
MOL. CANCER THER., vol. Vol.14 No.12 Suppl.2, JPN6022012251, 2015, pages 45, ISSN: 0005107994 *

Also Published As

Publication number Publication date
CA3051989A1 (en) 2018-08-23
US11406633B2 (en) 2022-08-09
TW201836610A (zh) 2018-10-16
EP3582811A1 (en) 2019-12-25
US20230063366A1 (en) 2023-03-02
CN117752784A (zh) 2024-03-26
AU2018221557A1 (en) 2019-08-15
IL268341B2 (en) 2023-06-01
KR20190112801A (ko) 2019-10-07
EP3582811B1 (en) 2024-07-10
IL268341A (en) 2019-09-26
US20190365746A1 (en) 2019-12-05
CN110267682A (zh) 2019-09-20
AU2018221557C1 (en) 2021-10-14
JP2022174157A (ja) 2022-11-22
RU2019128843A3 (enExample) 2021-05-17
TWI771372B (zh) 2022-07-21
KR20240007717A (ko) 2024-01-16
WO2018150312A1 (en) 2018-08-23
AU2018221557B2 (en) 2021-03-11
RU2767533C2 (ru) 2022-03-17
RU2019128843A (ru) 2021-03-16
MX2019009630A (es) 2019-11-08
JP2024133495A (ja) 2024-10-02

Similar Documents

Publication Publication Date Title
CN107567336B (zh) 癌症的联合治疗
TWI771372B (zh) Wnt抑制劑與抗-pd-1抗體分子組合之給藥方案
WO2018201056A1 (en) Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
TW202340473A (zh) 利用嵌合抗原受體之癌症治療
TW201615832A (zh) 使用人類化抗－ｂｃｍａ嵌合抗原受體治療癌症
JP2018518483A (ja) 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
EA038920B1 (ru) Комбинация антител к kir и антител к pd-1 для лечения злокачественной опухоли
JP2017517488A (ja) 抗ｃｄ１９キメラ抗原受容体を使用する癌の処置
JP2020517652A5 (enExample)
JP7402691B2 (ja) 抗ｃｄ２５抗体薬物複合体による併用療法
KR20190135028A (ko) 암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
JP2020517629A5 (enExample)
AU2020244756A1 (en) Compositions and methods for TCR reprogramming using fusion proteins
KR20200051024A (ko) 췌장암에 대한 조합 항-csf1r 및 항-pd-1 항체 조합 요법
JP7712496B2 (ja) 抗ｃｄ３９抗体及びその使用
CN114127315A (zh) 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
TW202309078A (zh) 治療癌症之方法及組成物
WO2022156727A1 (zh) 治疗肿瘤的组合物及方法
KR20230004635A (ko) Csf-1r에 의해 조절되는 질병을 치료하기 위한 투여 요법
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230628

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230721